XTX Topco’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

XTX Topco’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-23,594	Closed	-$11.8K	–	3306
2024 Q4	$11.8K	Buy	23,594 +1,157	+5%	+$3.3K	﹤0.01%	2125
2024 Q3	$83.7K	Buy	22,437 +2,233	+11%	+$10.7K	0.01%	1630
2024 Q2	$113K	Buy	+20,204	New	+$88K	0.01%	1391
2024 Q1	–	Sell	-25,751	Closed	-$135K	–	2443
2023 Q4	$135K	Buy	25,751 +10,701	+71%	+$106K	0.03%	1065
2023 Q3	$237K	Buy	+15,050	New	+$270K	0.04%	906

Other funds holding EGRX

SLG

Stanley-Laman Group Berwyn, Pennsylvania $984M AUM 72.08% 1-Year Est. Return

AIC

Archer Investment Corporation Carmel, Indiana $522M AUM 26.29% 1-Year Est. Return

XTX Topco's EGRX Position: Q1 2025 in Review

XTX Topco sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2025, closing a stake of 23,594 shares — an estimated $11.8K sold.

XTX Topco first reported a position in EGRX in Q3 2023 and held it in 5 quarters. The position peaked at $237K in Q3 2023. 2 funds tracked by Wall St. Rank hold EGRX as of Q1 2025.

XTX Topco reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2025 after selling out during the quarter.
XTX Topco sold 23,594 Eagle Pharmaceuticals, Inc. shares in Q1 2025, an estimated $11.8K.
XTX Topco first reported a position in Eagle Pharmaceuticals, Inc. in Q3 2023 and held it in 5 quarters.
XTX Topco's Eagle Pharmaceuticals, Inc. position peaked at $237K in Q3 2023.
2 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2025.

Based on XTX Topco's 13F filing for Q1 2025, filed 8 May 2025.